Fecal occult blood versus DNA testing: Indirect comparison in a colorectal cancer screening population

Clinical Epidemiology

Volumn 9, Issue , 2017, Pages 377-384

  Brenner, Hermann ^a   Chen, Hongda ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CANCER HOSPITAL   (China)

Author keywords

Colorectal cancer screening; Fecal immunochemical test; Fecal occult blood test; Sensitivity; Specificity; Test performance

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; FECAL IMMUNOCHEMICAL TEST; FEMALE; GERMANY; HUMAN; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTICS; MULTITARGET STOOL DNA TEST; OCCULT BLOOD TEST; PRECANCER; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RECTUM ADENOMA; SENSITIVITY AND SPECIFICITY;

EID: 85026457786     PISSN: None     EISSN: 11791349     Source Type: Journal    
DOI: 10.2147/CLEP.S136565     Document Type: Article

References (31)

1. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008;103(6): 1541–1549.
2. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61(7):1036–1040.
3. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369(12): 1106–1114.
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704–2714.
5. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer. 2013;49(14):3049–3054.
6. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287–1297.
8. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315(23):2576–2594.
9. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci. 2015;60(3):623–633.
10. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med. 2009;150(3):162–169.
11. Chen H, Werner S, Brenner H. Fresh vs frozen samples and ambient temperature have little effect on detection of colorectal cancer or adenomas by a fecal immunochemical test in a colorectal cancer screening cohort in Germany. Clin Gastroenterol Hepatol. Epub 2016 Oct 26.
12. R-Project [homepage on the Internet]. The R Project for Statistical Computing; Vienna, Austria. Available from: http://www.R-project.org/. Accessed March 31, 2016.
13. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer. 2011;128(10):2415–2424.
14. Parra-Blanco A, Gimeno-García AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol. 2010;45(7):703–712.
15. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ. 2011;183(13):1474–1481.
16. Brenner H, Werner S, Chen H. Multitarget stool DNA for colorectal-cancer screening. N Engl J Med. 2014;371(2):184–185.
17. Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening setting. Int J Biol Markers. 2006;21(3):157–161.
18. Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. Eur J Cancer. 2012;48(16):2969–2976.
19. Zubero MB, Arana-Arri E, Pijoan JI, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood tests. Front Pharmacol. 2014;4:175.
20. Santare D, Kojalo I, Huttunen T, et al. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. Eur J Gastroenterol Hepatol. 2015;27(5):536–543.
21. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011;33:101–110.
22. Stegeman I, van Doorn SC, Mundt MW, et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. Cancer Epidemiol. 2015;39(3):388–393.
23. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–463.
24. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010;153(6):368–377.
25. Lansdorp-Vogelaar I, Knudsen A, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev. 2011;33:88–100.
26. Sharp L, Tilson L, Whyte S, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer. 2012;106(5):805–816.
27. Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol. 2013;11(9):1158–1166.
28. Lejeune C, Le Gleut K, Cottet V, et al. The cost-effectiveness of immunochemical tests for colorectal cancer screening. Dig Liver Dis. 2014;46(1):76–81.
29. Ladabaum U, Alvarez-Osorio L, Rösch T, Brueggenjuergen B. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. Endosc Int Open. 2014;2(2):E96–E104.
30. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation. JAMA. 2016;315(23):2564–2575.
31. Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MC, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended? Gut. 2017;66(7):1262–1267.